Related Experiment Videos
How can one develop disease-modifying drugs in osteoarthritis?
1René Descartes University, Cochin Hospital, 27 rue du Faubourg, Saint Jacques, 75014 Paris, France. maxime.dougados@cch.ap-hop-paris.fr
Current Rheumatology Reports
|March 12, 2005
Summary
Developing disease-modifying osteoarthritis drugs requires careful consideration of outcome measures. Focus may be on structural, functional, or composite endpoints to assess cartilage breakdown intervention.
Area of Science:
- Rheumatology
- Pharmacology
- Biomedical Engineering
Background:
- Osteoarthritis (OA) is characterized by progressive cartilage breakdown.
- Disease-modifying OA drugs (DMOADs) aim to interfere with this pathological process.
- Current research focuses on defining optimal endpoints for OA clinical trials.
Purpose of the Study:
- To evaluate the most effective parameters for assessing DMOAD efficacy.
- To determine whether structural, functional, or composite indices are superior endpoints.
- To discuss the role of recent advancements in OA trial design.
Main Methods:
- Review of current strategies for OA clinical trial endpoint selection.
- Analysis of structural parameters (e.g., joint space width, cartilage volume via MRI).
- Evaluation of clinical parameters (e.g., functional impairment) and composite indices (e.g., need for joint replacement).
Main Results:
- The optimal endpoint for DMOAD trials remains a key question.
- Structural and functional parameters offer different insights into disease modification.
- Composite indices may provide a comprehensive assessment of treatment benefit.
Conclusions:
- The choice of endpoint in OA trials significantly impacts the assessment of DMOADs.
- Advances in imaging and biomarkers facilitate earlier phase studies.
- Further consensus is needed on the most relevant and reliable outcome measures for OA drug development.